Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker BLCO
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 28, 2026 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 28, 2026 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 13, 2026 | BLCO Bausch + Lomb Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 13, 2026 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 12, 2026 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K/A | 8-K ↗ |
| Aug 6, 2026 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 6, 2026 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 6, 2026 | BLCO Bausch + Lomb Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 29, 2026 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 20, 2026 | BLCO Bausch + Lomb Corporation | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 29, 2026 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 18, 2026 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 2, 2026 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Jan 2, 2026 | BLCO Bausch + Lomb Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jan 2, 2026 | BLCO Bausch + Lomb Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Dec 22, 2025 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K/A | 8-K ↗ |
| Dec 17, 2025 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Dec 12, 2025 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 13, 2025 | BLCO Bausch + Lomb Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 29, 2025 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 18, 2025 | BLCO Bausch + Lomb Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 18, 2025 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 18, 2025 | BLCO Bausch + Lomb Corporation | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 30, 2025 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 23, 2025 | BLCO Bausch + Lomb Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 27, 2025 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 27, 2025 | BLCO Bausch + Lomb Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jun 27, 2025 | BLCO Bausch + Lomb Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jun 18, 2025 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 10, 2025 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| May 21, 2025 | BLCO Bausch + Lomb Corporation | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 21, 2025 | BLCO Bausch + Lomb Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Apr 30, 2025 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 19, 2025 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 1, 2024 | BLCO Bausch + Lomb Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Nov 1, 2024 | BLCO Bausch + Lomb Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 30, 2024 | BLCO Bausch + Lomb Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
37 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances